Reported recently by Alabama News Center, “Researchers at the University of Alabama at Birmingham have identified a potential pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer.” Published in the Journal of Clinical Investigation, the research was performed in both animal models and human and mouse cells in culture. An adhesive cell surface protein known as N-cadherin – or N-cad – may be key in overcoming glioblastoma’s resistance to radiation therapy, according to the findings.
Even with top-of-the-line surgery, radiation and chemotherapies, “glioblastoma patients’ survival is less than two years on average. While radiation is a frequently used therapy to kill tumor cells, medical scientists have long known that in glioblastomas some tumor cells are resistant to radiation. Those surviving cells continue to reproduce and spread throughout the brain, leading to tumor regrowth,” reported Alabama News Center.
Clusterin inhibitors are being analyzed in clinical trials, and this study provides the rationale for testing them in glioblastoma in conjunction with radiation therapy to prevent the emergence of resistance.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).